Korean company takes on US with AI rare disease diagnosis, highlighting technological capabilities to develop market - Korean media

Three Billion, a company that uses artificial intelligence (AI) to provide diagnostic solutions for rare diseases, is preparing to enter the U.S. market. It is expected to set up a corporation in Texas within the first half of the year.
The company is poised to demonstrate its AI technology capabilities in its competition with GeneDX Holdings, a major U.S. company in the industry.
The company's CEO, Kum Chang-won, believes that 2025 is the right time to enter the US market.
This is because JenDX Holdings, the parent company of JenDX, has yet to secure AI technological capabilities. "JenDX recently announced an AI model, but the performance was very low," said CEO Kum.
After establishing a US subsidiary, the company is looking into collaborating with South Korean genetic analysis solutions company SomerGen to sell its products, and also plans to market to hospitals.
However, the company does not expect rapid growth in the US market, as it is difficult for a Korean company to successfully sell to US hospitals in a short period of time.
The company also aims to achieve results within three years. It plans to turn a profit by 2027. Its sales in 2024 are expected to be 5.8 billion won (approximately 592.61 million yen), more than double the previous year.
The operating loss was 7.4 billion won (about 756.2 million yen).